Search
Search
About
Log in
Join
Experiences with
Glecaprevir / Pibrentasvir
Posts
Communities
10 public posts
Filter results
Is glecaprevir and pibrentasvir combination therapy effective?
#HCV #Treatment #
glecaprevir
#
pibrentasvir
http://bit.ly/2kTBoLx
#HCV #Treatment #
glecaprevir
#
pibrentasvir
http://bit.ly/2kTBoLx
HFIAdmin
in
Hepatitis C Support
8 years ago
Is glecaprevir and pibrentasvir combination therapy effective?
#HCV #Treatment #
glecaprevir
#
pibrentasvir
http://bit.ly/2kTBoLx
#HCV #Treatment #
glecaprevir
#
pibrentasvir
http://bit.ly/2kTBoLx
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
FDA grants priority review for AbbVie's pan-genotypic HCV regimen
It has been weeks since AbbVie's New #Drug Application for
glecaprevir
/
pibrentasvir
. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9
It has been weeks since AbbVie's New #Drug Application for
glecaprevir
/
pibrentasvir
. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA grants priority review for AbbVie's pan-genotypic HCV regimen
It has been weeks since AbbVie's New #Drug Application for
glecaprevir
/
pibrentasvir
. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9
It has been weeks since AbbVie's New #Drug Application for
glecaprevir
/
pibrentasvir
. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9
HFIAdmin
in
Hepatitis C Support
8 years ago
AbbVie submits NDA for investigational regimen for all HCV genotypes
AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of
glecaprevir
/
pibrentasvir
for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ
AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of
glecaprevir
/
pibrentasvir
for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
AbbVie submits NDA for investigational regimen for all HCV genotypes
AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of
glecaprevir
/
pibrentasvir
for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ
AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of
glecaprevir
/
pibrentasvir
for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ
HFIAdmin
in
Hepatitis C Support
8 years ago
VIDEO: Pangenotypic regimen leads to high SVR in all HCV genotypes
After treatment with AbbVie’s new pangenotypic regimen of
glecaprevir
/
pibrentasvir
, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr
After treatment with AbbVie’s new pangenotypic regimen of
glecaprevir
/
pibrentasvir
, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr
HFIAdmin
in
Hepatitis C Support
8 years ago
VIDEO: Pangenotypic regimen leads to high SVR in all HCV genotypes
After treatment with AbbVie’s new pangenotypic regimen of
glecaprevir
/
pibrentasvir
, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr
After treatment with AbbVie’s new pangenotypic regimen of
glecaprevir
/
pibrentasvir
, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
Glecaprevir/pibrentasvir shows safety, efficacy in patients with HCV, renal disease
A recent study has shown that 102 out of 104 HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe
A recent study has shown that 102 out of 104 HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
Glecaprevir/pibrentasvir shows safety, efficacy in patients with HCV, renal disease
A recent study has shown that 102 out of 104 #HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (#hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe
A recent study has shown that 102 out of 104 #HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (#hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe
HFIAdmin
in
Hepatitis C Support
8 years ago
Filter results
Clear filters
Posted in
All communities
Hepatitis C Support
5 results
HFI Connect - Hepatitis
5 results
Sort by
Most Relevant
Newest